Condition: Follicular Lymphoma · Marginal Zone Lymphoma · Sponsor: Enterome
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
This description comes directly from the study's public registry record.
Jan Fagerberg, MD, PhD · +32 3 205 55 55 · medicalmonitoring-hem@enterome.com
Karlijn Kroon, MD · +33 611300589 · kkroon-ext@enterome.com
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) | Rochester, New York, United States | Recruiting |
| University of Washington-Seattle Cancer Care Alliance | Seattle, Washington, United States | Recruiting |
| CHU d'Amiens-Picardie - Hopital SUD | Amiens, France | Recruiting |
| University of Bologna | Bologna, Italy | Withdrawn |
| IRCCS Policlinico San Matteo Foundation - University of Pavia | Naples, Italy | Recruiting |
| IRCCS Policlinico San Matteo Foundation - University of Pavia | Pavia, Italy | Recruiting |
| University Hospital Vall d'Hebron, Institute of Oncology | Barcelona, Spain | Recruiting |
| Clinica Universidad de Navarra | Madrid, Spain | Recruiting |
| Clinica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Hospital Clinico Universitario de Salamanca | Salamanca, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04669171